Importance: Antimicrobial resistance data from bacterial keratitis in Australia are lacking.
INTRODUCTION
Antimicrobial resistance (AMR) is a global health threat recognized across patient populations and is predicted to escalate in the future. The World Health Organization Global Action Plan 1 recommends AMR surveillance to underpin disease prevention and control strategies, including evidence-based antibiotic prescribing guidelines. This was recently highlighted in the medical and ophthalmic literature. [2] [3] [4] [5] [6] Bacterial keratitis is an ophthalmic emergency requiring immediate, effective antibiotic treatment as it can progress rapidly, causing visual impairment and corneal blindness, [7] [8] [9] with significant collateral costs including reduced a quality of life for the individual and increased health-system burden. [7] [8] [9] [10] [11] In the elderly, eye loss and blindness are reported respectively in 10% and 40% patients. 12 In children, permanent vision loss due to amblyopia can be a complication. 13 The Sydney Eye Hospital is a quaternary referral unit for eye diseases in Sydney, New South Wales, Australia, providing surgical and medical management of patients in New South Wales with corneal, vitreo-retinal, glaucoma, oculo-plastic, uveitis and oculo-oncology conditions. The Sydney Eye Hospital treats more than 200 patients with bacterial keratitis each year.
The current recommendations for the initial treatment of bacterial keratitis in Australia, according to Therapeutic Guidelines -Antibiotic, Version 15, 2014 14 are: ciprofloxacin 0.3% (Ciloxan, Alcon, Australia) or ofloxacin 0.3% (Ocuflox, Allergan, Australia) or fortified cefalotin 5% plus gentamicin 0.9%. Systematic reviews have identified similar efficacy with these regimes but a higher rate of ocular surface toxicity with fortified antibiotics. 15 However, surveillance data on AMR from ocular isolates are required to inform current therapeutic guidelines. 16 To this end, we have established a surveillance system at Sydney Eye Hospital, with the view to expand and include data from across Australia so that the AMR profile of organisms isolated from corneal scrapes can result in informative, future national treatment guidelines.
The aims of this study were to identify the types of bacteria isolated from corneal scrapes from patients clinically diagnosed with microbial keratitis at the Sydney Eye Hospital, and to determine their antibiotic susceptibility profiles.
METHODS
A retrospective analysis of the cohort of patients presenting with clinical bacterial keratitis and who had positive bacterial cultures from corneal scrapes during the period January 1 to December 31, 2016 was conducted. Corneal scrapes were taken in accord with the clinical protocol in patients who had a clinical diagnosis of keratitis at presentation to the Sydney Eye Hospital. 17 Specimens were smeared onto a glass slide, and a Gram-stain was performed to guide empiric treatment. For bacterial cultures the following solid media were inoculated and incubated at 35 C in different conditions: Horse blood Columbia agar incubated anaerobically; Chocolate Columbia agar, incubated in 5% CO 2 ; and Saponin lysed horse blood Columbia agar, incubated in air. The agar plates were examined for growth at 24 and 48 h. In addition, an enrichment liquid medium was inoculated and incubated at 35 C. After 48 h the liquid media was sub-cultured onto Horse blood Columbia agar (incubated anaerobically), Chocolate Columbia agar (incubated in 5% CO 2 ) and MacConkey agar (incubated in air). All plates were examined for growth at 24 and 48 h. Bacteria were identified by matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry using an Ultraflex LT with v 3.0 software (Bruker Daltonics, Bremen, Germany).
Antibiotic susceptibilities were determined by the Calibrated Dichotomous Sensitivity (CDS) method 18 and the Minimum Inhibitory Concentration (MIC) breakpoints for resistance were in accord with those specified in the CDS method for systemic isolates. There are no MIC breakpoints for any method of susceptibility testing which relate to the concentration of an antibiotic at the local site after its topical administration.
The susceptibility of Staphylococcus aureus to cefalotin was extrapolated from testing cefoxitin. The susceptibility of coagulase-negative Staphylococci to cefalotin was extrapolated from testing oxacillin. The susceptibility of Streptococcus pneumoniae/Corynebacterium spp. to cefalotin was extrapolated from testing penicillin. The susceptibility of staphylococci, Corynebacterium spp., and Pseudomonas aeruginosa to ofloxacin was extrapolated from testing ciprofloxacin. The susceptibility of Streptococcus pneumoniae to ofloxacin and ciprofloxacin was extrapolated from testing moxifloxacin.
RESULTS
In 2016, 224 corneal scrapes were undertaken in patients with clinical keratitis collected at Sydney Eye Hospital. Culture was positive in 168 samples (75%) growing 157 organisms. One hundred and thirty-one patients had a single organism isolated and 21 had mixed bacterial growth.
The total number of Gram-positive and Gramnegative isolates was 131 (83%) ( Table 1) and 26  (17%) (Table 2) , respectively. The antibiotic susceptibility profiles of the commonly isolated organisms are shown in Tables 3-5 and 6 .
Gram-positive organisms
Of the 131 Gram-positive organisms, 75 (57%) were coagulase-negative Staphylococci, 15 (11%) were Staphylococcus aureus (including one methicillinresistant isolate), eight (6%) were Streptococcus pneumoniae and eight (6%) were Corynebacterium spp.
Gram-positive antibiotic resistance
Of the methicillin-sensitive Staphylococcus aureus (MSSA), 21% (n = 3) were resistant to chloramphenicol and 7% (n = 1) to ciprofloxacin and gentamicin. Of the coagulase-negative Staphylococci, resistance was 9% (n = 6) to cefalotin, 4% (n = 3) to chloramphenicol, 9% (n = 7) to ciprofloxacin and 9% (n = 7) to gentamicin. All Staphylococci were susceptible to vancomycin (Table 3) . Of the Corynebacterium spp., 40% (n = 2) were resistant to cefalotin, 25% (n = 2) to chloramphenicol and 14% (n = 1) to ciprofloxacin. There was no resistance to vancomycin ( Table 4) . None of the Streptococcus pneumoniae isolates was resistant to chloramphenicol, ciprofloxacin, vancomycin or cefalotin (Table 5 ).
Gram-negative organisms
Of the 27 Gram-negative organisms, 15 (58%) were Pseudomonas aeruginosa, four (15%) Serratia spp. and three (12%) Moraxella spp.
Gram-negative antibiotic resistance
Pseudomonas aeruginosa is inherently resistant to cefalotin, chloramphenicol and vancomycin. Of the 15 isolates, 7% (n = 1) were resistant to ciprofloxacin. None were resistant to gentamicin or tobramycin (Table 6) .
DISCUSSION
This study from the Sydney Eye Hospital showed that, in our setting in 2016, culture was positive in 168 of 224 inoculated plates (75%). Together, Staphylococci, Streptococcus pneumoniae, Corynebacterium spp. and Pseudomonas aeruginosa were the most commonly isolated organisms and comprised 121 (77%) of the total numbers (157). It is known that a spectrum of bacterial isolates and their associated antibiotic susceptibilities vary between different geographic locations, shifting trends with time. Our study was conducted in Sydney, Australia over one calendar year. The predominant cause of bacterial keratitis in our isolate-based surveillance program were Gram- positive organisms, with the majority being coagulase-negative Staphylococci (CoNS), similar to other studies in Australia, United States, Israel, Canada, France, New Zealand. 19 The CoNS proportion was 38% in Sydney, 19 30% in Adelaide 20 and Perth (15%). 21 The proportion of Gram-negative organisms (17%) was low comparing with other studies. The proportion was 29% in Melbourne, 11 29% in Sydney, 19 28% in Adelaide, 20 48% in Perth, 21 37% in Houston 22 and 21% in Los Angeles. 23 Low proportion of resistance to cefalotin and ofloxacin/ciprofloxacin was detected in our study for Staphyloccocal species. The cefalotin resistance for CoNS (9%) was lower than in Adelaide (35%) 20 and Brisbane (34%).
24 All 14 S. aureus (100%) were susceptible to cefalotin as described in a previous study in Sydney (100%). 19 For CoNS, the ofloxacin/ ciprofloxacin resistance was 9%, similar to the resistance reported in previously in Sydney (10%) 19 and Brisbane (6%). 24 For S. aureus, the resistance to ofloxacin/ciprofloxacin in our study was 7%, higher than in Adelaide (0%), 20 Sydney (0%) 19 and Melbourne 4%. 25 However, the proportion of ciprofloxacin resistance for CoNS in USA is much higher as described in Houston (27%), and for S. aureus in South Florida (28%) and Pittsburgh (35%). 26 Moreover, no resistance to vancomycin for gram-positives was found in our study as reported in Brisbane, 24 Melbourne, 25 Houston 22 and Toronto. 27 Pseudomonas spp. were sensitive to ofloxacin/ciprofloxacin in 93% of cases, lower than reported in previous studies in Sydney (100%), 19 Los Angeles (100%), 23 Brisbane 24 and Toronto (97.8%) 27 and 100% sensitive to gentamicin. Pseudomonas spp. are inherently resistant to cefalotin, chloramphenicol and vancomycin.
The current empiric treatment recommendations from Therapeutic Guidelines -Antibiotic, Version 15, 2014 14 are ciprofloxacin 0.3% eye drops or ofloxacin 0.3% eye drops, or cefalotin 5% plus gentamicin 0.9% eye drops. Oral or intravenous antibiotics do not have a role in the management of uncomplicated bacterial keratitis. Of the four most common groups of organisms identified (Staphylococci, Streptococcus pneumoniae, Corynebacterium spp. and Pseudomonas aeruginosa); more than 90% would be covered by the current therapeutic recommendation of ciprofloxacin or ofloxacin, as would the alternative recommendation of cefalotin and gentamicin in combination.
The World Health Organization proposes that 5% resistance is the threshold for action for change of empirical therapy for neonatal sepsis and for sexually transmitted infections, 28, 29 but there is not such threshold for bacterial keratitis. In this era of increasing antimicrobial resistance it is vital to monitor AMR and provide an evidence base for developing empirical guidelines for serious infections. Whilst these data suggest that the recommended current empiric therapy for bacterial keratitis would provide cover for most of the organisms which were isolated, we recognize the limitations of this study. These include single centre, relatively small numbers and lack of comparison in our setting. However, the strengths of these data include consecutive samples tested with a single method in a tertiary centre laboratory service. Further, susceptibility patterns change according to climate and geographical region and can fluctuate from time to time. 30 The US evaluation of resistance in ocular specimen has been followed through the TRUST (Tracking Resistance in the US Today) program as the 'Ocular TRUST' initiated in 2005 and the ARMOR (Antibiotic Resistance Monitoring in Ocular Microorganisms) initiative initiated in 2009. Together these two programs follow the resistance patterns of Staphylococcus aureus, Streptococcus pneumonia, Haemophilus influenza (TRUST) and Pseudomonas aeruginosa and CoNS (ARMOR). 31 A networked system, coordinated nationally is urgently needed in Australia to provide wider scale information on AMR in bacterial keratitis. We provide these data for discussion and consideration as we take the first steps to a networked Australia wide programme for monitoring AMR in bacterial keratitis.
